Compare Johnson & Johnson (JNJ) vs JPMorgan Chase & Co (JPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs JPMorgan Chase & Co — how do they compare? Johnson & Johnson trades at $256.5 (market cap $618.09B), while JPMorgan Chase & Co trades at $333.14 (market cap $880.98B). The key difference: JPMorgan Chase & Co is the larger of the two by market cap, and Johnson & Johnson pays the higher dividend (2.09%). Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and JPMorgan Chase & Co for 127 Days on average.
| JNJ | JPM | |
|---|---|---|
Market Cap | $618.09B | $880.98B |
Volume | 6,050,983 | 7,721,661 |
Sector | Health | Financials |
52-Week High | $278.43 | $365.18 |
52-Week Low | $186.00 | $282.84 |
Typical Hold Time | 129 Days | 127 Days |
Enterprise Value | $646.37B | $1.82T |
Dividend Yield | 2.09% | 1.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $259.62, up 0.45% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 21.48% net margin and 25.74% ROE, though valuation ratios appear elevated with P/E at 29.75. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with 52.5% buy ratings.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and increasing debt-to-asset ratio (24.06% in 2025). Analyst consensus target of $286.53 suggests 10% upside potential, though technical resistance at $260 may limit near-term gains.
JPMorgan Chase & Co. (JPM) trades at $332.39, up 0.85% daily, with a bearish technical signal but strong fundamentals. Recent earnings show two beats out of three reported quarters, with Q3 2026 results pending. Revenue grew to $181.85B in 2025, though net income dipped to $57.05B. The stock is supported by a high ROE of 18.43% and a moderate P/E of 14.2, while analyst consensus is a 'Moderate Buy' with a $373.18 price target.
Outlook remains positive due to solid profitability and institutional support, but risks include geopolitical tensions, cybersecurity threats highlighted in recent news, and volatile cash flows. The stock offers value relative to peers, with upside potential if earnings momentum continues, though investors should monitor macroeconomic headwinds and upcoming Q3 earnings for direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →
